Beyond borders 2014 - Overview of the biotechnology landscape

Abstract

The global biotechnology industry rebounded strongly in 2013. Public companies achieved doubledigit revenue growth and there was a sharp rise in funds. Product successes have boosted revenues, drawn investors and motivated large companies to invest strongly in R&D. However, much of the industry's growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts.